Skip to content

Calcitriol in acute kidney transplant rejection

The effect of calcitriol on the incidence of acute rejection among kidney transplant recipients, A pilot, double-blind, randomized placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260104068546N1
Enrollment
30
Registered
2026-02-18
Start date
2026-01-21
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation, acute rejection atfer kidney transplantation.

Interventions

Intervention 1: Intervention group: two pearl of calcitriol 0.25 micrograms per-oral for one month. Intervention 2: Control group: two pearl of placebo per-oral for one month.

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: living/deceased donor kidney transplant patients in imam khomeini hospital aged over 18 years old serum calcium less than 10.5 mg/dL serum phosphorus less than 6 mg/dL

Exclusion criteria

Exclusion criteria: Participate in other interventional clinical studies at the same time retransplantation pregnancy or lactation Simultaneous transplantation of multiple organs Previous intolerance/allergy to vitamin D supplements or calcitriol History of desensitization for transplantation Blood iPTH level less than 50 pg/dL Blood 25 OH-vitamin D3 level over 100 ng/mL Cold ischemia duration more than 4 hours Patient's lack of consent to the study Not receiving defined immunosuppression regimen

Design outcomes

Primary

MeasureTime frame
Incidence of acute rejection. Timepoint: during first 3 months post kidney transplantation. Method of measurement: kidney biopsy proven or clinical suspicion with clinical cure post corticostroid puls administration.

Secondary

MeasureTime frame
Comparison of time of first acute rejection episode between two group. Timepoint: during first 3 months post transplant. Method of measurement: biopsy proven or clinically suspicion which responds to corticostroid puls.;Comparison of allograft function based on eGFR between two groups. Timepoint: 3 months post transplantation. Method of measurement: measurement of eGFR based on MDRD formula.;Comparison of incidence and kind of infection episodes between two groups. Timepoint: during 3 months post kidney transplantation. Method of measurement: clinical observation and laboratory findings.;Comparison of hospital stay during first hospitalisation post transplantation. Timepoint: during 3 months post kidney transplantation. Method of measurement: hospital documentation.;Comparison of patient survival and graft survival. Timepoint: during 3 months post kidney transplantation. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOfogh Bigdeli

Tehran University of Medical Sciences

ofogh.bigdeli@yahoo.com+98 21 6119 2085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026